Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
Conley
B A
BA
Division of Development Therapeutics, University of Maryland Cancer Center, Baltimore.
Egorin
M J
MJ
Sinibaldi
V
V
Van Echo
D A
DA
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004334:Drug Administration Schedule; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D017290:Menogaril; D008875:Middle Aged; D009621:Nogalamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism; D011446:Prospective Studies
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D017290:Menogaril; D009621:Nogalamycin